Kamada (KMDA) Scheduled to Post Earnings on Wednesday

Kamada (NASDAQ:KMDA - Get Free Report) is scheduled to be announcing its earnings results before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of $0.07 per share for the quarter. Kamada has set its FY 2024 guidance at EPS.Parties that wish to listen to the company's conference call can do so using this link.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. The business had revenue of $42.47 million for the quarter, compared to analysts' expectations of $39.70 million. Kamada had a net margin of 9.75% and a return on equity of 6.15%. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Trading Down 0.2 %

NASDAQ:KMDA traded down $0.01 during mid-day trading on Thursday, hitting $5.98. The stock had a trading volume of 41,051 shares, compared to its average volume of 29,020. The stock has a 50-day simple moving average of $5.42 and a two-hundred day simple moving average of $5.43. The company has a market capitalization of $343.73 million, a PE ratio of 22.19 and a beta of 1.05. Kamada has a twelve month low of $4.58 and a twelve month high of $6.53.

Analyst Ratings Changes

Several equities analysts have commented on KMDA shares. HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, August 15th. StockNews.com downgraded Kamada from a "strong-buy" rating to a "buy" rating in a report on Tuesday, August 27th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.